Cyclooxygenase-2 (COX-2) was recently reported (M. Tsujii and R. N. DuBois, Cell, 83: 493-501, 1995) to affect the metastatic potential of cells. Previous studies (M. Fukuda,
Cancer Res., 56: 2237-2244, 1996) indicated that sialyl Lewis
antigen expression is correlated with hematogenous
metastasis of
colon cancer. In the present study, we investigated the interaction between COX-2 activity, expression of
sialyl Lewis antigens, in vitro
cancer cell adhesion to endothelial cells, and in vivo metastatic potential. Effects of COX-2 activity and
prostaglandin E(2) on cell adhesion, expression of
sialyl Lewis antigens, and
glycosyltransferase genes were determined in Caco-2-m (COX-2 low level), Caco-2-COX-2 (programmed to overexpress COX-2), and HT-29 (COX-2 high level) cells. Metastatic spread of these cells to the liver was also investigated. Caco-2-COX-2 cells had increased SPan-1 levels and increased adherence to endothelial cells via SPan-1 compared with Caco-2-m cells. HT-29 cells expressed
sialyl Lewis a and adhered to endothelial cells via
sialyl Lewis a. Treatment with a
COX-2 inhibitor,
celecoxib, decreased SPan-1 and
sialyl Lewis a expression and adherence to endothelial cells. beta 3Gal-T5 and
ST3Gal III and IV expression was inhibited by
celecoxib and was enhanced by
prostaglandin E(2) treatment. Caco-2-COX-2 and HT-29 cells metastasized to the liver, whereas Caco-2-m cells did not. Pretreatment with
celecoxib reduced the metastatic potential as well as anti-sialyl Lewis
antibodies. Our results indicate a direct link between COX-2 and enhanced adhesion of
carcinoma cells to endothelial cells, and enhanced liver metastatic potential via accelerated production of
sialyl Lewis antigens.
COX-2 inhibitors may suppress
metastasis.